shown granulocyte macrophage-colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine, is upregulated in the uterus in a mouse model of preterm birth. We have also shown treatment with an antibody to GM-CSF will prevent preterm birth within six hours. Therefore, we hypothesized treatment with an antibody to GM-CSF will prevent the upregulation of contraction associated proteins in the uterus leading to preterm birth. STUDY DESIGN: For this study, we utilized a mouse model of preterm birth. On embryonic day 17, pregnant CD1 mice were anesthetized and received an intrauterine injection of lipopolysaccharide (LPS) along with either an intravenous injection of anti-mouse GM-CSF or control antibody. After six hours the uteri were harvested and analyzed for expression of the oxytocin transmembrane receptor (OXTR), cyclooxygenase-2 (COX-2), or connexin-43 (Cx43) using quantitative polymerase chain reaction (qPCR). RESULTS: LPS increased the expression of COX-2 (p<0.001) compared to mice receiving an intrauterine injection of saline, and treatment with the anti-mouse GM-CSF antibody resulted in a decreased expression of COX-2 (p<0.05). Treatment with LPS did not increase the expression of OXTR or Cx43 compared to control mice, although the GM-CSF antibody did decrease the expression of Cx43 compared to mice treated with the control antibody.
OBJECTIVE:
To assess the fetal neuroprotective potential of 17-hydroxyprogesterone (17OHP) and identify mechanisms for its benefit, using a novel mouse model of chronic maternal systemic inflammation. STUDY DESIGN: Using a mouse model of chronic maternal systemic inflammation involving daily intraperitoneal (IP) injections of 1mg IL-1b to CD-1 timed-pregnant dams from E15 to E18, we have previously shown that IL-1b administration results in impaired pup survival and neurodevelopmental outcomes, along with significant placental upregulation of NFkB2 and CXCL11 compared to controls. In our current experiment, CD-1 timed-pregnant dams were randomly assigned to three groups: IP phosphate buffered saline (PBS, n¼8), IP IL-1b (n¼13), or IP IL-1b + subcutaneous 17OHP (IL-1b/P, n¼10). PBS or IL-1b was administered daily from E15 to E18 with 17OHP injected 1h prior to IL-1b in randomly selected dams. Fetal brains and placentas of E18 embryos were collected 6h after final IL-1b injections and individual qPCR analyses were carried out for the following immune markers: CCL2, CCL3, CXCL9, CXCL10, CXCL11, NFkB1, NFkB2, IL-1b, IL-6, and TNFa. Additionally, flow cytometry of E18 placentas was carried out for CD3 + CD4 + and CD3 + CD8 + cells. Pups that did not undergo tissue harvesting underwent neurodevelopmental assessment at PND5 and PND9. Data were analyzed using c 2 test and ANOVA, as appropriate. RESULTS: IL-1b/P pups exhibited significantly improved performance on neurodevelopmental assessment compared IL-1b pups (Figure 1 ). QPCR analysis of immune markers in placentas revealed that 17OHP significantly reduced NFk B1 (P ¼ .0352) with a nonsignificant trend towards lower levels of IL-6 and NFkB2 (Figure 2 ). Placental CD4/CD8 ratios were significantly decreased in IL-1b/P pups compared to IL-1b pups (P < .05). CONCLUSION: 17OHP improves offspring neurodevelopment in pregnant dams exposed to IL-1b-initiated chronic inflammation. Placental immunomodulation via reduction in expression of transcription factors involved in cellular responses to inflammation and reduction in inflammatory cytokines are potential mechanisms by which 17OHP confers a beneficial immunomodulatory effect on the placenta that can be neuroprotective and warrants further investigation.
536 Timing of corticosteroids for preterm premature rupture of membranes at 22 weeks: a decision analysis Clarice G. Zhou, James Sargent, Aaron B. Caughey
Oregon Health & Science University, Portland, OR OBJECTIVE: Despite their benefits, there is evidence that the effects of antenatal corticosteroids decrease 7 days after treatment, thus the timing of antenatal corticosteroids following presentation impacts neonatal outcomes. The objective of this study was to use a decision analysis to determine the optimal time for steroid administration for women with preterm premature ruptures (PPROM) of membranes at 22 weeks. STUDY DESIGN: A decision-analytic model was constructed using TreeAge software to compare the neonatal mortality and morbidity following antenatal corticosteroid treatment in a theoretical cohort of 1,000 women who present with PPROM at 22 weeks. The model compared administering steroids immediately at presentation (22 weeks) or in subsequent weeks (23-26 weeks gestation) following presentation. The outcomes of neonatal death, respiratory distress syndrome, intraventricular hemorrhage, and neurodevelopmental delay were assessed along with maternal and neonatal qualityadjusted life years (QALYs). All probabilities, utilities, and costs were derived from literature. Costs are expressed in 2018 US dollars with a willingness to pay threshold (WTP) set at $100,000/QALY. Deterministic and probabilistic sensitivity analyses were performed to interrogate model assumptions. RESULTS: In our theoretical cohort of 1,000 women who present with PPROM at 22 weeks, administering antenatal corticosteroids three weeks after presentation (at 25 weeks gestation) resulted in 44
Poster Session III ajog.org additional survivors compared to immediate administration at 22 weeks. Overall, delaying administration of antenatal steroids by three weeks led to higher QALYS when compared to immediate treatment. However, there would be 10 more neonates with respiratory distress syndromes, 20 more intraventricular hemorrhage, and 11 more children with neurodevelopmental delay. With sensitivity analysis, we found that as long as the probability of survival at 25 weeks gestation is less than 81%, then delaying administration by three weeks remains the optimal strategy. CONCLUSION: Our results support that the optimal time for administration of antenatal corticosteroids in women with PPROM at 22 weeks is three weeks after presentation at 25 weeks gestation to reduce mortality and minimize morbidity. These findings can be used to counsel women presenting in the periviable period.
537 Timing of antenatal corticosteroids for severe preeclampsia at 22 weeks: a decision analysis Clarice G. Zhou, James Sargent, Aaron B. Caughey
Oregon Health & Science University, Portland, OR OBJECTIVE: Preterm delivery secondary to preeclampsia have severe neonatal complications, although incidences can be reduced with antenatal corticosteroid treatment. Despite their benefits, there is evidence that the effects of steroids decrease 7 days after treatment, thus the timing of administration following presentation impacts neonatal outcomes. The objective of this study was to use a decision analysis to determine the optimal time for steroid administration for women with severe preeclampsia at 22 weeks. STUDY DESIGN: A decision-analytic model was constructed using TreeAge software to compare neonatal mortality and morbidity following steroid treatment in a theoretical cohort of 1,000 women who present with severe preeclampsia at 22 weeks. The model compared administering steroids immediately at presentation (22 weeks), at 1 week (23 weeks), and at 2 weeks (24 weeks) following presentation. The outcomes of neonatal death, respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), and neurodevelopmental delay were assessed along with quality-adjusted life years (QALYs). All probabilities, utilities, and costs were derived from literature. Costs are expressed in 2018 US dollars with a willingness to pay threshold (WTP) set at $100,000/QALY. Deterministic and probabilistic sensitivity analyses were performed to interrogate model assumptions. RESULTS: In our theoretical cohort of 1,000 women who present with preeclampsia at 22 weeks, administering steroids one week after presentation resulted in 12 additional survivors compared to immediate treatment at 22 weeks and 163 more survivors compared to waiting until week 24. Giving steroids at 23 weeks gestation led to 16 fewer neonates with RDS, 32 fewer neonates with IVH, and 12 fewer children with neurodevelopmental delay. Overall, delaying administration of antenatal steroids by one week led to higher QALYS when compared to immediate treatment. With sensitivity analysis, we found that as long as the probability of survival at 23 weeks gestation is less than 55%, then delaying administration remains the optimal strategy.
CONCLUSION:
Our results support that the optimal time for administration of antenatal corticosteroids in women with severe preeclampsia at 22 weeks is one week after presentation at 23 weeks gestation to reduce morbidity and mortality. These findings can be used to counsel women presenting in the periviable period. OBJECTIVE: This study analyzes differences in maternal and neonatal outcomes from elective induction of labor (eIOL) at 39 weeks versus one additional week of expectant management in nulliparous women at community hospitals. STUDY DESIGN: We conducted a retrospective cohort study of singleton, vertex, nonanomalous deliveries in community hospitals in California between 2007 and 2011 using linked hospital discharge and vital statistics data (n¼252,107). We compared outcomes from eIOL, defined by the Joint Commission, at 39 weeks against one additional week of expectant management and delivery at 40 weeks. The maternal outcomes of interest were cesarean delivery, operative vaginal delivery, maternal blood transfusion, perineal tear, chorioamnionitis, and endomyometritis. Neonatal outcomes of interest were intrauterine fetal death, 5 minute Apgar less than 7, NICU admission, respiratory distress syndrome (RDS), hypoglycemia, hypoxic ischemic encephalopathy (HIE) and jaundice. Results were compared using chi square analysis and examined using multivariate logistic regression controlling for maternal age, comorbidities, ethnicity, education level, initiation of prenatal care in the first trimester, and insurance status. A p-value of less than 0.05 was used to indicate statistical significance. RESULTS: In our cohort of 252,107 deliveries, there were significant differences in the incidence of cesarean delivery, operative vaginal delivery, maternal transfusion, perineal tear, chorioamnionitis, endomyometritis in women who were electively induced at 39 weeks compared to those who received expectant management and delivered at 40 weeks. Rates of adverse neonatal outcomes of intrauterine fetal death and hypoglycemia were also significantly decreased when women were electively induced at 39 weeks. However, RDS, HIE and jaundice were not significantly different between the two groups. Logistic regression analysis indicated expectant management until 40 weeks significantly increased cesarean deliveries (OR 1.37, 95% CI 1.32-1.42) and operative vaginal deliveries (OR 1.0, 95% CI 1.02-1.15). CONCLUSION: The maternal and neonatal outcomes following birth are associated with the timing and management prior to delivery. These findings can be used to counsel women regarding the risks of maternal and neonatal complications from elective induction of labor and one additional week of expectant management.
